Tanja Obradovic: Some points of interest from the Relativity-104 study

Tanja Obradovic shared on LinkedIn:

“Opdualag, a cocktail of anti Lag-3 (relatlimab) and anti PD1 (nivolumab) Abs, was recently approved for the treatment of adult and pediatric patients with unresectable or metastatic melanoma. After disappointing results in CRC, liver and gastric cancer interesting to see that advances may be coming in NSCLC.

PhII Relativity-104 study will be presented at incoming ESMO while Relativity- 1093 PhIII has just been posted and is to start recruitment. Results of Relativity-104 (1st line NSCLC in combination with chemo in squamous and nonsquamous NSCLC) will be known post ESMO but opening of the PhIII indicates positivity at least to some extent.

Unlike Relativity-104, PhIII Relativity-1093 limits 1st line patient population to those with nonsquamous histology and requires PDL1 expression of 1-49%. Interesting to see details and magnitude of treatment effect at ESMO 2024 of Relativity-104 outcome that informed this PhIII design. Another point of interest is that control arm in Relativity-1093 is chemo combo with keytruda so truly relevant comparison of data will be coming.”

Read further.
Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.